A two-stage drop-the-losers design for time-to-event outcome using a historical control arm

被引:0
|
作者
Abbas, Rachid [1 ,2 ]
Wason, James [3 ,4 ]
Michiels, Stefan [1 ,2 ]
Le Teuff, Gwenael [1 ,2 ]
机构
[1] Gustave Roussy, Biostat & Epidemiol Dept, Villejuif, France
[2] Univ Paris Saclay, Ligue Canc, INSERM, Oncostat U1018, Villejuif, France
[3] Newcastle Univ, Populat Hlth Sci Inst, Newcastle Upon Tyne, Tyne & Wear, England
[4] Univ Cambridge, MRC Biostat Unit, Cambridge, England
关键词
adaptive design; historical control; oncology phase II trials; one-sample log-rank; time-to-event; SURVIVAL TRIAL DESIGN; CLINICAL-TRIALS; SAMPLE;
D O I
10.1002/pst.2168
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Phase II immuno-oncology clinical trials screen for efficacy an increasing number of treatments. In rare cancers, using historical control data is a pragmatic approach for speeding up clinical trials. The drop-the-losers design allows dropping off ineffective arms at interim analyses. We extended the original drop-the-losers design for a time-to-event outcome using a historical control through the one-sample log-rank statistic. Simulated trials featured three arms at the first stage, one at the second stage, nine scenarios, eight sample sizes with 5%- and 10%- nominal family-wise error rate (FWER). A numerical algorithm is provided to solve power calculations at the design stage. Our design was compared with a group of three independent single-arm trials (fixed design) with and without correction for multiplicity. Our design allowed strict control of the FWER at nominal levels while the misspecification of survival distribution and fixed design inflated the FWER up to three times the nominal level. The empirical power of our design increased with the sample size, the treatment effect and the number of effective treatments and dropped when more patients were recruited at the second stage. The fixed design with correction showed comparable power, while our design advantageously included more patients to the most promising arm. Recommendations for future applications are given. By taking advantage of the use of historical control data and a time-to-event outcome, the drop-the-losers design is a promising tool to meet the challenge of improving phase II clinical trials in immuno-oncology.
引用
收藏
页码:268 / 288
页数:21
相关论文
共 50 条